Sentiment for Verastem Inc (NASDAQ:VSTM)
/Verastem Inc (NASDAQ:VSTM) Institutional Investors Sentiment Index Worsens in 2018 Q4
Verastem Inc (NASDAQ:VSTM) institutional sentiment decreased to 1.12 in 2018 Q4. Its down -0.62, from 1.74 in 2018Q3. The ratio has dropped, as 48 hedge funds started new and increased equity positions, while 43 sold and trimmed holdings in Verastem Inc. The hedge funds in our partner’s database now have: 41.14 million shares, up from 34.34 million shares in 2018Q3. Also, the number of hedge funds holding Verastem Inc in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 20 Reduced: 23 Increased: 28 New Position: 20.
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $225.80 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.
